Managers / Q1 2026
Mass General Brigham, Inc
CIK 0001678378 · 399 REVOLUTION DRIVE, SUITE 612, SOMERVILLE, MA, 02145 · 8572777268
Summary
Mass General Brigham, Inc reported $469M in U.S.-listed holdings across 6 positions for Q1 2026.
The portfolio is heavily concentrated: ACWI alone accounts for 62.4% of reported value.
Compared with Q4 2025, the fund opened 0 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- ETP · 62.4% · $293M
- Common Stock · 37.6% · $176M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| MDLNMEDLINE INC | ADDED | +44.1K | 70.4K | +$2M | $3M |
| RBRKRUBRIK INC | SOLD OUT | −14.0K | 0 | −$1M | $0 |
| ACWIISHARES TR | TRIMMED | −2.46M | 2.15M | −$360M | $293M |
| KRMNKARMAN HLDGS INC | HELD | +0 | 1.56M | +$11M | $125M |
| RVMDREVOLUTION MEDICINES INC | HELD | +0 | 344.1K | +$6M | $33M |
| TNGXTANGO THERAPEUTICS INC | HELD | +0 | 354.2K | +$4M | $7M |
| MAZEMAZE THERAPEUTICS INC | HELD | +0 | 240.0K | −$3M | $7M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ACWIISHARES TRhistory → | MSCI ACWI ETF | 62.42% | $293M | 2.15M |
| 2 | KRMNKARMAN HLDGS INChistory → | COM | 26.67% | $125M | 1.56M |
| 3 | RVMDREVOLUTION MEDICINES INChistory → | COM | 7.14% | $33M | 344.1K |
| 4 | TNGXTANGO THERAPEUTICS INChistory → | COM | 1.58% | $7M | 354.2K |
| 5 | MAZEMAZE THERAPEUTICS INChistory → | COM | 1.53% | $7M | 240.0K |
| 6 | MDLNMEDLINE INC | COM | 0.67% | $3M | 70.4K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $469M | 6 | May 5, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $810M | 7 | Jan 27, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $44M | 5 | Oct 16, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $21M | 4 | Jul 31, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $57M | 5 | Apr 4, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $28M | 2 | Jan 24, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $11M | 2 | Oct 23, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | Under review | 7 | Jul 21, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $128,310 | 6 | Apr 5, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | Under review | 5 | Jan 19, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $192M | 3 | Oct 19, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $214M | 3 | Jul 27, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $235M | 5 | Apr 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $282M | 7 | Jan 19, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $371M | 7 | Oct 8, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $410M | 9 | Jul 19, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $639M | 3 | Apr 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $473M | 3 | Feb 8, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $126M | 2 | Oct 23, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $290M | 3 | Jan 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $436M | 3 | Oct 30, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $153M | 1 | Jul 29, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $162M | 1 | Apr 18, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $144M | 1 | Jan 30, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.